HC Wainwright Has Positive Outlook for Zura Bio Q3 Earnings

Zura Bio Limited (NASDAQ:ZURA - Free Report) - Analysts at HC Wainwright lifted their Q3 2025 earnings per share (EPS) estimates for Zura Bio in a note issued to investors on Monday, November 11th. HC Wainwright analyst M. Kapoor now expects that the company will earn ($0.23) per share for the quarter, up from their previous estimate of ($0.24). HC Wainwright currently has a "Neutral" rating and a $5.00 target price on the stock. The consensus estimate for Zura Bio's current full-year earnings is ($0.61) per share.

Zura Bio (NASDAQ:ZURA - Get Free Report) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.12).

Several other research firms have also weighed in on ZURA. Leerink Partners assumed coverage on Zura Bio in a research note on Monday, November 4th. They issued an "outperform" rating and a $15.00 price objective on the stock. Cantor Fitzgerald restated an "overweight" rating on shares of Zura Bio in a research note on Friday, October 18th. Piper Sandler reiterated an "overweight" rating and set a $26.00 target price on shares of Zura Bio in a research report on Thursday, September 19th. Chardan Capital cut their price target on shares of Zura Bio from $14.00 to $12.00 and set a "buy" rating for the company in a report on Friday, November 8th. Finally, Leerink Partnrs raised shares of Zura Bio to a "strong-buy" rating in a research note on Monday, November 4th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Zura Bio presently has a consensus rating of "Buy" and an average price target of $15.80.

Zura Bio Price Performance

Shares of Zura Bio stock traded down $0.15 during trading on Wednesday, hitting $4.38. 260,950 shares of the company's stock traded hands, compared to its average volume of 325,384. Zura Bio has a twelve month low of $2.00 and a twelve month high of $6.35. The firm's fifty day moving average price is $4.21 and its 200 day moving average price is $4.13.

Institutional Investors Weigh In On Zura Bio

Institutional investors have recently modified their holdings of the business. Affinity Asset Advisors LLC acquired a new stake in shares of Zura Bio during the first quarter worth $1,157,000. Bank of New York Mellon Corp raised its position in shares of Zura Bio by 15.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 47,109 shares of the company's stock valued at $165,000 after acquiring an additional 6,412 shares during the period. Renaissance Technologies LLC boosted its stake in Zura Bio by 51.3% during the 2nd quarter. Renaissance Technologies LLC now owns 17,400 shares of the company's stock worth $61,000 after acquiring an additional 5,900 shares during the last quarter. Great Point Partners LLC increased its stake in Zura Bio by 68.3% in the second quarter. Great Point Partners LLC now owns 4,642,241 shares of the company's stock valued at $16,248,000 after purchasing an additional 1,884,501 shares in the last quarter. Finally, Armistice Capital LLC raised its holdings in Zura Bio by 53.2% in the second quarter. Armistice Capital LLC now owns 2,524,000 shares of the company's stock worth $8,834,000 after purchasing an additional 876,000 shares during the period. Institutional investors and hedge funds own 61.14% of the company's stock.

Insiders Place Their Bets

In other Zura Bio news, Director Someit Sidhu sold 51,728 shares of the company's stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $3.87, for a total transaction of $200,187.36. Following the transaction, the director now owns 2,085,418 shares of the company's stock, valued at approximately $8,070,567.66. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 22.10% of the company's stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.